Guidelines
Therapeutic Recommendations

Therapeutic Recommendations

Clinical Guidance from BC COVID-19 Therapeutics Committee (CTC)

Summary (infographic) and Detailed recommendations for specific therapies

Clinical Evidence Review

Severely Ill Patients

Critically Ill Patients

Prescribing of IL-6 inhibitor (e.g. Tocilizumab) therapy requires second clinical opinion from Intensivist or Internist working in ICU if not already consulted/involved, to confirm therapy is appropriate

Supply memo

NH Order Set (Updated: Feb 14, 2022)

Other Agents

Critically ill: not recommended outside of approved clinical trials

Severely ill: has not demonstrated benefit in survival, progression to ventilation or length of hospital stay and remains uncertain with respect to shortening time to recovery by 5 days. The World Health Organization (WHO) has issued a conditional recommendation against the use of remdesivir in severely ill hospitalized COVID-19 patients.

Mild - moderately ill: see mild - moderately ill section above

Additional Information

Questions related to these guidelines can be directed to Alicia Rahier, Antimicrobial Stewardship Pharmacist, at

If you require advice for a severely or critically ill COVID-19 patient contact the Regional COVID-19 Intensivist on call via UHNBC switchboard (250-565-2000)